Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts Q3 results and reports positive Phase 2 MaGic trial data in gMG
Dianthus Therapeutics Inc. reported a net loss of $36.8 million, or $0.97 per share, for the quarter ended September 30, 2025, compared to a net loss of $25.2 million, or $0.74 per share, for the same period in 2024. The company estimates an adjusted cash, cash equivalents, and investments position of approximately $525.0 million as of September 30, 2025, after accounting for upfront and near-term milestone payments related to the licensing of DNTH212 from Nanjing Leads Biolabs. This cash position is projected to provide funding runway into 2028. Recent business developments include the closing of an upsized public offering raising about $288.0 million and the exclusive licensing agreement for DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569561-en) on November 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。